New Science Direct publication (dated August 2022)
Post# of 148155
(Total Views: 1127)
Posted On: 07/23/2022 4:11:24 PM
New Science Direct publication (dated August 2022) - cut below:
CCR5. Leronlimab (also known as PRO 140) is a humanized IgG4 mAb that binds the C-C chemokine receptor type 5 (CCR5). In COVID-19, disrupting the C-C chemokine ligand 5 (CCL5)-CCR5 axis with leronlimab may limit the pulmonary trafficking of pro-inflammatory leukocytes and decrease pathogenic immune activation. Two CTs are assessing the efficacy of leronlimab in patients with COVID-19 (NCT04901689 and NCT04347239).
https://www.sciencedirect.com/science/article...6922002703
CCR5. Leronlimab (also known as PRO 140) is a humanized IgG4 mAb that binds the C-C chemokine receptor type 5 (CCR5). In COVID-19, disrupting the C-C chemokine ligand 5 (CCL5)-CCR5 axis with leronlimab may limit the pulmonary trafficking of pro-inflammatory leukocytes and decrease pathogenic immune activation. Two CTs are assessing the efficacy of leronlimab in patients with COVID-19 (NCT04901689 and NCT04347239).
https://www.sciencedirect.com/science/article...6922002703
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼